Hyperthyroidism in childhood: causes, when and how to treat

Area of Science:

• Pediatric Endocrinology
• Autoimmune Diseases
• Thyroid Disorders

Background:

• Graves' disease (GD) is the leading cause of pediatric hyperthyroidism.
• Antithyroid drugs (ATD) are the primary treatment, but high relapse rates (30%) pose a significant challenge.
• Prolonged ATD therapy can increase remission rates to 50%.

Purpose of the Study:

• To review and update the management strategies for pediatric Graves' disease.
• To identify prognostic indicators for ATD remission in children with GD.
• To discuss alternative treatments and management of neonatal hyperthyroidism.

Main Methods:

• Literature review of current management practices for pediatric Graves' disease.
• Analysis of factors influencing remission rates and relapse risk with ATD.
• Discussion of prognostic indicators for stratifying patients.

Main Results:

• Longer duration of initial ATD treatment significantly reduces relapse risk.
• Predictive factors for relapse include severe hyperthyroidism at diagnosis, young age, and co-existing autoimmune conditions.
• Stratification based on these factors aids in tailoring treatment, including long-term ATD or early alternative therapies.

Conclusions:

• Optimizing ATD treatment duration and utilizing prognostic indicators can improve outcomes in pediatric Graves' disease.
• Early diagnosis and management of neonatal hyperthyroidism are crucial due to potential risks.
• Monitoring thyroid hormone receptor antibodies in pregnant women with GD is essential for offspring health.